|Edward M. Schaeffer, MD, PhD|
|Debasish Sundi, MD|
In addition, the PCMDC offers a unique opportunity for research. For instance, many patients speak favorably about their experience at PCMDC, however little data exists validating these perceptions. Over the next several months, we will be evaluating the patient-centered experience at the Johns Hopkins PCMDC by prospectively evaluating quality of life, satisfaction with care, and illness uncertainty among patients coping with a new diagnosis of prostate cancer. The study is conducted entirely online and is administered through the NIH-funded tool for online clinical research: Assessment Center (www.assessmentventer.net). Patients complete online questionnaires before and after their clinic appointment and can access their personalized study webpage from their personal computers, tablets, or smart phones. By focusing on patient-reported outcomes, our goal is to show a positive impact of multidisciplinary cancer care on the quality of life of men with newly diagnosed prostate cancer. In addition, research opportunities exist to track cancer and functional outcomes following surgery and radiation treatments. Novel therapies including gene-based vaccinations are offered to appropriate candidate patients. Patients with advanced malignancies who have failed traditional therapies are offered the newest and latest options from Johns Hopkins experts.
If you are a patient with prostate cancer who would like a second opinion, or if you are a physician with a patient who you would like seen at PCMDC please call 410-955-6100.
1. Aizer AA, Paly JJ, Zietman AL, et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 1;30(25):3071-6. doi: 10.1200/JCO.2012.42.8466. Epub 2012 Jul 30.
3. Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, Raben MG, Song DY, Drake CG, Netto GJ, Macura KJ, DeWeese TL, Partin AW, Bivalacqua TJ, Ross AE, Schaeffer EM. Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification. To be presented at GU-ASCO, January 30-February 1, 2014; San Francisco, California.